SEARCH

SEARCH BY CITATION

References

  • Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, et al (2011) The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3: 111ra120
  • Antonarakis SE, Valle D, Moser HW, Moser A, Qualman SJ, Zinkham WH (1984) Phenotypic variability in siblings with Farber disease. J Pediatr 104: 406- 409
  • Bar J, Linke T, Ferlinz K, Neumann U, Schuchman EH, Sandhoff K (2001) Molecular analysis of acid ceramidase deficiency in patients with Farber disease. Hum Mutat 17: 199- 209
  • Beckham TH, Lu P, Cheng JC, Zhao D, Turner LS, Zhang X, Hoffman S, Armeson KE, Liu A, Marrison T, et al (2012) Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int J Cancer 131: 2034- 2043
  • Bielawska A, Perry DK, Hannun YA (2001) Determination of ceramides and diglycerides by the diglyceride kinase assay. Anal Biochem 298: 141- 150
  • Bokhove M, Yoshida H, Hensgens CM, van der Laan JM, Sutherland JD, Dijkstra BW (2010) Structures of an isopenicillin N converting Ntn-hydrolase reveal different catalytic roles for the active site residues of precursor and mature enzyme. Structure 18: 301- 308
  • Boring L, Gosling J, Cleary M, Charo IF (1998) Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894- 897
  • Burek C, Roth J, Koch HG, Harzer K, Los M, Schulze-Osthoff K (2001) The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells. Oncogene 20: 6493- 6502
  • Cvitanovic-Sojat L, Gjergja Juraski R, Sabourdy F, Fensom AH, Fumic K, Paschke E, Levade T (2011) Farber lipogranulomatosis type 1 – late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation. Eur J Paediatr Neurol 15: 171- 173
  • Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J (2007) Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 5: 15- 21
  • Ehlert K, Roth J, Frosch M, Fehse N, Zander N, Vormoor J (2006) Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach. Ann Rheum Dis 65: 1665- 1666
  • Eliyahu E, Park JH, Shtraizent N, He X, Schuchman EH (2007) Acid ceramidase is a novel factor required for early embryo survival. FASEB J 21: 1403- 1409
  • Eliyahu E, Shtraizent N, Shalgi R, Schuchman EH (2012) Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility. Cell Physiol Biochem 30: 735- 748
  • Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, Bravo R, Lira SA (1995) Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 155: 5769- 5776
  • Haraoka G, Muraoka M, Yoshioka N, Wakami S, Hayashi I (1997) First case of surgical treatment of Farber's disease. Ann Plast Surg 39: 405- 410
  • Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, et al (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772- 777
  • Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494- 1505
  • Kolesnick R (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110: 3- 8
  • Levade T, Leruth M, Graber D, Moisand A, Vermeersch S, Salvayre R, Courtoy PJ (1996) In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin. J Lipid Res 37: 2525- 2538
  • Levade T, Moser HW, Fensom AH, Harzer K, Moser AB, Salvayre R (1995) Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. J Neurol Sci 134: 108- 114
  • Levade T, Sandhoff K, Schulze H, Medin JA (2009) Acid ceramidase deficiency: Farber lipogranulomatosis. In Scriver's OMMBID (Online Metabolic and Molecular Bases of Inherited Disease), Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A (eds), New York: McGraw-Hill
  • Li CM, Park JH, He X, Levy B, Chen F, Arai K, Adler DA, Disteche CM, Koch J, Sandhoff K, et al (1999) The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics 62: 223- 231
  • Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, Ehleiter D, Paris F, Manova K, Hepbildikler S, et al (2002) Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79: 218- 224
  • Loughran TP, Wang HG (2011) Editorial [hot topic: Therapeutic targeting of the sphingolipid “biostat” in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang). Anticancer Agents Med Chem 11: 780- 781
  • Lucki NC, Sewer MB (2011) Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J Biol Chem 286: 19399- 19409
  • Maceyka M, Harikumar KB, Milstien S, Spiegel S (2012) Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22: 50- 60
  • Medin JA, Takenaka T, Carpentier S, Garcia V, Basile JP, Segui B, Andrieu-Abadie N, Auge N, Salvayre R, Levade T (1999) Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. Hum Gene Ther 10: 1321- 1329
  • Mitsutake S, Date T, Yokota H, Sugiura M, Kohama T, Igarashi Y (2012) Ceramide kinase deficiency improves diet-induced obesity and insulin resistance. FEBS Lett 586: 1300- 1305
  • Moser HW, Moser AB, Chen WW, Schram AW (1989) Ceramidase deficiency: Farber lipogranulomatosis, In: The Metabolic Basis of Inherited Disease, Vol. II, 6th edition, Scriver CR, Beaudet AL, Sly WS, Valle D (eds) pp. 1645- 1654 New York: McGraw-Hill
  • Munoz-Olaya JM, Matabosch X, Bedia C, Egido-Gabas M, Casas J, Llebaria A, Delgado A, Fabrias G (2008) Synthesis and biological activity of a novel inhibitor of dihydroceramide desaturase. ChemMedChem 3: 946- 953
  • Nagy A, Gertsensten M, Vintersten K, Behringer R (2003) Manipulating the Mouse Embryo; A Laboratory manual, 3rd edition, New York: Cold Spring Harbor Press, Cold Spring Harbor
  • Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604- 616
  • Park JH, Schuchman EH (2006) Acid ceramidase and human disease. Biochim Biophys Acta 1758: 2133- 2138
  • Pellissier JF, Berard-Badier M, Pinsard N (1986) Farber's disease in two siblings, sural nerve and subcutaneous biopsies by light and electron microscopy. Acta Neuropathol 72: 178- 188
  • Popovic K, Prive GG (2008) Structures of the human ceramide activator protein saposin D. Acta Crystallogr D Biol Crystallogr 64: 589- 594
  • Qualman SJ, Moser HW, Valle D, Moser AE, Antonarakis SE, Boitnott JK, Zinkham WH (1987) Farber disease: pathologic diagnosis in sibs with phenotypic variability. Am J Med Genet 3: 233- 241
  • Ramsubir S, Nonaka T, Girbes CB, Carpentier S, Levade T, Medin JA (2008) In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab 95: 133- 141
  • Rutledge BJ, Rayburn H, Rosenberg R, North RJ, Gladue RP, Corless CL, Rollins BJ (1995) High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol 155: 4838- 4843
  • Samad F, Hester KD, Yang G, Hannun YA, Bielawski J (2006) Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55: 2579- 2587
  • Sands MS, Barker JE (1999) Percutaneous intravenous injection in neonatal mice. Lab Anim Sci 49: 328- 330
  • Shtraizent N, Eliyahu E, Park JH, He X, Shalgi R, Schuchman EH (2008) Autoproteolytic cleavage and activation of human acid ceramidase. J Biol Chem 283: 11253- 11259
  • Sugita M, Dulaney JT, Moser HW (1972) Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science 178: 1100- 1102
  • Theunissen JW, Petrini JH (2006) Methods for studying the cellular response to DNA damage: influence of the Mre11 complex on chromosome metabolism. Methods Enzymol 409: 251- 284
  • Walia JS, Neschadim A, Lopez-Perez O, Alayoubi A, Fan X, Carpentier S, Madden M, Lee CJ, Cheung F, Jaffray DA, et al (2011) Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther 22: 679- 687
  • Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F (2009) Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 297: E211- E224
  • Yeager AM, Uhas KA, Coles CD, Davis PC, Krause WL, Moser HW (2000) Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant 26: 357- 363
  • Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, Murray GJ, Poeppl AG, Underwood J, West L, et al (2004) Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101: 16909- 16914
  • Zarbin MA, Green WR, Moser HW, Morton SJ (1985) Farber's disease. Light and electron microscopic study of the eye. Arch Ophthalmol 103: 73- 80
  • Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9: 40- 47
  • Zhang Z, Mandal AK, Mital A, Popescu N, Zimonjic D, Moser A, Moser H, Mukherjee AB (2000) Human acid ceramidase gene: novel mutations in Farber disease. Mol Genet Metab 70: 301- 309